ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / BNTC / options
IRD (23) VOGX (45) PRLD (33) ENTA (20) ⌘ Pro Terminal →

Benitec Biopharma Inc. (BNTC) Options Positioning, Max Pain & Unusual Sweeps

$8.74 -1.02% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.71

Benitec Biopharma Inc. (BNTC) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $304.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BNTC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BNTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Benitec Biopharma Inc. (NASDAQ: BNTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $8.74 (-1.02% 1D, market cap $304.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BNTC ranks #796 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BNTC compare to IRD and VOGX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BNTC carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRD (Opus Genetics Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $305.3M) and VOGX (Vogenx Inc) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $300.8M). Among the 5-stock peer group, BNTC leads on earnings multiple (N/A) while BNTC leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BNTC?
▼

Per BNTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001808898), Benitec Biopharma Inc. generated $116.9M in revenue (+85.7% YoY), -$37.9M in net income, and -$23.6M in free cash flow against $190.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $8.71 (-0.37%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (8)Whales (3)SEC (10)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.6% Base Target
$17 Bull$8 Base$6 Bear
📬 FREE BNTC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BNTC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY BNTC SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
22
Grade E$8.63+4.8% Next Q
Q2 (-2Q)
25
Grade E$9.04-4% Next Q
Q3 (-1Q)
27
Grade E$8.68+0.7% Next Q
Current
30
Grade E$8.74-9.6% Hist 90D α
Trajectory: E (22) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BNTC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BNTC currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.22) and Max Pain ($9.18) forces dealer call-delta covering toward $17.13.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BNTC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BNTC Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (BNTC)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for BNTC.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BNTC)

  • ✓Walkthrough of BNTC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BNTC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.24%▼ DESCENDING CHANNEL
2026-11-03O $8.83H $8.83L $8.74C $8.74VOL 135.5K
RES: $13.53SUP: $7.44SMA50: $10.22SMA200: $11.51
$14.78$12.91$11.05$9.18$7.31RES $13.53SUP $7.44$8.742026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BNTC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BNTC Butterfly Map → + Track BNTC →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BNTC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BNTC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BNTC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BNTC)

Health Care Rank #796 of 1016 ⚔️ IRD vs BNTC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BNTC vs. IRD, VOGX, PRLD, ENTA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Benitec Biopharma Inc. (BNTC) ranks #796 by composite RQD confidence (30/100, grade E) and #515 by equity capitalization ($304.9M). Within this direct 5-issuer industry benchmark cohort, BNTC leads on earnings valuation at N/A trailing P/E, while BNTC leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VOGX currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with BNTC at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BNTC ACTIVE
Benitec Biopharma Inc.
E 30/100 — — -35.0% -1.02% $304.9M Benchmark Subject
IRD
Opus Genetics Inc.
E 23/100 — — -35.0% +0.55% $305.3M /ird-vs-bntc →
VOGX
Vogenx Inc
D 45/100 — — — +1.66% $300.8M /vogx-vs-bntc →
PRLD
Prelude Therapeutics Incorporated
E 33/100 — — -35.0% -5.37% $309.6M /prld-vs-bntc →
ENTA
Enanta Pharmaceuticals Inc.
E 20/100 — — -35.0% -3.95% $311.9M /enta-vs-bntc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001808898

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Benitec Biopharma Inc. (BNTC) reported GAAP revenue of $116.9M (+85.7% vs. FY2024 revenue of $63.0M , and +118.9% cumulative change since FY2023) , GAAP net income of -$37.9M, operating cash flow of -$23.6M, and free cash flow of -$23.6M (-20.5% YoY). On the balance sheet, BNTC closed FY2025 with $190.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $116.9M -$37.9M -$23.6M -$23.6M $190.7M —
FY2024 (FY) 2024-06-30 $63.0M -$21.8M -$19.4M -$19.6M $79.1M —
FY2023 (FY) 2023-06-30 $53.4M -$19.6M -$18.0M -$18.0M — —

3. BNTC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BNTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Benitec Biopharma Inc. (NASDAQ: BNTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $8.74 (-1.02% 1D, market cap $304.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BNTC ranks #796 in composite RQD confidence.

How does BNTC compare to IRD and VOGX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BNTC carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRD (Opus Genetics Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $305.3M) and VOGX (Vogenx Inc) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $300.8M). Among the 5-stock peer group, BNTC leads on earnings multiple (N/A) while BNTC leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BNTC?

Per BNTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001808898), Benitec Biopharma Inc. generated $116.9M in revenue (+85.7% YoY), -$37.9M in net income, and -$23.6M in free cash flow against $190.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BNTC trading relative to its 50-day, 200-day, and 52-week technical levels?

BNTC last traded at $8.74 (-1.02% on volume of 135,494 shares), positioning the stock -14.48% below its 50-day simple moving average ($10.22) and -24.07% below its 200-day simple moving average ($11.51). Across its 52-week range of $7.89 to $16.31, BNTC sits at the 10.1% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.65 to $9.83).

Direct Sub-Reports: BNTC RQD Cockpit BNTC 12M Forecast BNTC Earnings & Move BNTC Dividends & DRIP BNTC Insiders & 13F BNTC Whale Options BNTC Profit Sankey BNTC News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BNTC — Benitec Biopharma Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:38:39Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, BNTC carries an RQD Score of 30 and a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars score as follows: Fundamental Cash Engine 8/20 (ROIC -35%; FCF yield -7.66%), Whale 13F Flow 3/20, Insider Conviction 3/20, Macro Regime Fit 6/20 (Beta 1.0), and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). The weakest pillars are institutional flow and insider conviction, each at 3 out of 20. The cash engine score is also low, consistent with the negative ROIC and negative free cash flow yield. The forensic balance sheet pillar is the relative strength, with a Debt/Equity of 0.5 and an Altman Z of 2.5, though the Piotroski F of 2/9 signals weak financial health across the checks. For a prospective investor evaluating the stock today, the rating frames the current setup as high forensic risk. This brief is analytical and educational, not personalized advice.

Business

Benitec Biopharma Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, the most prominent items are: a regulatory update following a Type C meeting with the FDA regarding the BB-301 pivotal study (flagged YELLOW, MARKET WIRE); a TradingView report of a 12-month price target raised to $24.33, implying 171% upside (GREEN, CATALYST); Raymond James initiating coverage with an Outperform rating and a $14 price target (GREEN, CATALYST); and a Stock Titan report that every patient in the company's study responded to an experimental treatment for a disease that weakens swallowing (YELLOW, MARKET WIRE). A Benzinga initiation roundup also references BNTC (GREEN, CATALYST). Risk watch items: the feed includes only headline-level summaries and does not provide trial sample sizes, timelines, or regulatory terms. The butterfly supply-chain graph reports no supply-chain links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations. Investors should watch whether the pivotal-study regulatory path, referenced in the news feed, affects the company's ability to fund operations given its reported negative free cash flow, since the source does not describe the company's funding structure beyond reported cash.

Open Questions

  • What is the funding runway given reported FY 2025 free cash flow of $-23.6M against $188.8M in cash?
  • What are the timeline, endpoints, and enrollment details of the BB-301 pivotal study referenced in the FDA regulatory update?
  • Why are revenue, EPS, and debt reported as — or N/A across all periods, and what is the company's primary business model?
  • What drove the reported cash increase from $78.3M to $188.8M between FY 2024 and FY 2025?
  • What analyst consensus and holder data would confirm or challenge the Raymond James initiation and the cited price target?

BNTC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Benitec Biopharma Inc. (BNTC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BNTC Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BNTC Bull vs. Bear Conversation Board — What's Your Call at $8.74?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BNTC 🐻 67% BEARISH CONVICTION
1. Pick Your Side on BNTC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $7.77 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is BNTC (E • RQD 30/100) a Buy at $8.83?

Welcome to the BNTC (Benitec Biopharma Inc.) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $7.24 (-18.0%)
Spot @ $8.83

Pump the brakes on BNTC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BNTC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Benitec Biopharma Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $11.13 (+26.0%)
Spot @ $8.83

BNTC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BNTC, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $8.83 (52-wk range $7.89 - $16.68), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%